Managing Operational Surprises in Real Time - Insights
While preparation is key to mitigating risk, inevitably, there are unforeseen circumstances that will impact operations. Here are four ways the outreach laboratory can swiftly manage operational surprises in real time.
New Year's Specimen Shipping Guidelines and Schedule - Insights
Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered for the New Year's holiday. To ensure specimen viability and minimize delays, the following adjustments and guidelines have been implemented and will be...
Christmas Holiday Shipment Schedules - Insights
The United States will observe the Christmas holiday on Monday, Dec. 25. On this day, Mayo Clinic Laboratories will be open; however, specimen shipments and deliveries to our laboratories will not be made by the carriers. To safeguard...
Mayo Clinic researchers identify new disease subtype linked to recurrent blood clots - Insights
Mayo Clinic researchers identify a new subtype of MGTS, linked to recurrent blood clots, with significant diagnostic challenges and treatment implications.
The Expanding Reach of the Laboratory Outreach Program - Insights
The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and...
Severe storms affecting FedEx hub in Memphis, TN - Insights
Due to severe weather affecting the FedEx hub in Memphis, Tennessee, delays are anticipated. The Mayo Clinic Laboratories’ Global Logistics team will be diverting work to other commercial shipping options.
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Top 5 Mayo Clinic Laboratories advancements in 2024 - Insights
Five of the most significant advancements from Mayo Clinic Laboratories in 2024 to enhance diagnostics and patient care globally.
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
Mayo Clinic Laboratories and Lucence are expanding access to advanced cancer testing worldwide with LiquidHALLMARK®, a next-generation liquid biopsy that provides actionable genomic insights. This collaboration empowers physicians to...